BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR442970 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR442970\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06958536-9657@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SAR442970: Phase 2 readout est. (NCT06958536)
DESCRIPTION:SAR442970\, phase 2.\nStudy: A Study to Investigate Efficacy an
 d Safety of Brivekimig in Participants With Crohn's Disease\nEstimated pri
 mary completion: 17 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sar442970#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06958536
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975722-9657@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SAR442970: Phase 2 readout est. (NCT06975722)
DESCRIPTION:SAR442970\, phase 2.\nStudy: A Study to Investigate the Efficac
 y and Safety of Brivekimig in Adult Participants With Ulcerative Colitis\n
 Estimated primary completion: 17 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sar442970#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06975722
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500702-9657@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:SAR442970: Phase 2 readout est. (NCT06500702)
DESCRIPTION:SAR442970\, phase 2.\nStudy: A Study to Evaluate the Efficacy a
 nd Safety of Frexalimab\, Brivekimig\, or Rilzabrutinib in Participants Ag
 ed 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minim
 al Change Disease\nEstimated primary completion: 23 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sar442970#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06500702
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170917-9657@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:SAR442970: Phase 2 readout est. (NCT07170917)
DESCRIPTION:SAR442970\, phase 2\, Hidradenitis Suppurativa.\nStudy: Briveki
 mig for the Treatment of Moderate to Severe Hidradenitis Suppurativa\nEsti
 mated primary completion: 9 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sar442970#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07170917
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812988-9657@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:SAR442970: Phase 2 readout est. (NCT06812988)
DESCRIPTION:SAR442970\, phase 2.\nStudy: Treatment of Type 1 Diabetes With 
 Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecu
 le\nEstimated primary completion: 29 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sar442970#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06812988
URL:https://assetmemo.bio/drug/sar442970#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
